TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Sol-Gel Technologies ( (SLGL) ).
On August 27, 2025, Sol-Gel Technologies announced Health Canada’s approval of EPSOLAY for treating rosacea in adults, marking a significant milestone in their partnership with Searchlight Pharma. This approval is expected to strengthen Sol-Gel’s financial position through potential milestone payments and royalties, supporting their growth strategy and global commercialization plans for EPSOLAY and TWYNEO. The company is also exploring strategic alternatives for its acne and rosacea business as these are no longer core focuses.
Spark’s Take on SLGL Stock
According to Spark, TipRanks’ AI Analyst, SLGL is a Neutral.
Sol-Gel Technologies’ stock score reflects significant financial performance challenges due to negative profitability and cash flow issues. Positive technical indicators offer some short-term optimism, but the lack of valuation appeal and guidance from earnings calls creates uncertainty. Strategic financial improvements and clearer future guidance would be needed to enhance the stock’s attractiveness.
To see Spark’s full report on SLGL stock, click here.
More about Sol-Gel Technologies
Sol-Gel Technologies Ltd. is a dermatology company focused on developing and commercializing treatments for severe skin conditions. The company has developed products like TWYNEO and EPSOLAY, approved for acne vulgaris and rosacea respectively, and is conducting clinical trials for other dermatological therapies.
Average Trading Volume: 23,725
Technical Sentiment Signal: Buy
Current Market Cap: $66.02M
Learn more about SLGL stock on TipRanks’ Stock Analysis page.